Cancer Chemotherapy and Pharmacology

, Volume 68, Issue 1, pp 165–175

Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study

Authors

  • Dong-Yeop Shin
    • Department of Internal MedicineSeoul National University Hospital, Seoul National University College of Medicine
  • Sae-Won Han
    • Department of Internal MedicineSeoul National University Hospital, Seoul National University College of Medicine
    • Cancer Research InstituteSeoul National University College of Medicine
    • Department of Internal MedicineSeoul National University Hospital, Seoul National University College of Medicine
    • Cancer Research InstituteSeoul National University College of Medicine
  • Seock-Ah Im
    • Department of Internal MedicineSeoul National University Hospital, Seoul National University College of Medicine
    • Cancer Research InstituteSeoul National University College of Medicine
  • Tae-You Kim
    • Department of Internal MedicineSeoul National University Hospital, Seoul National University College of Medicine
    • Cancer Research InstituteSeoul National University College of Medicine
  • Yung-Jue Bang
    • Department of Internal MedicineSeoul National University Hospital, Seoul National University College of Medicine
    • Cancer Research InstituteSeoul National University College of Medicine
Original Article

DOI: 10.1007/s00280-010-1454-2

Cite this article as:
Shin, D., Han, S., Oh, D. et al. Cancer Chemother Pharmacol (2011) 68: 165. doi:10.1007/s00280-010-1454-2

Abstract

Purpose

The role of 18F FDG-PET in hepatocellular carcinoma (HCC) has not been firmly established. We conducted this study to investigate the clinical implication of SUVmax on 18F FDG-PET as a prognostic factor in patients with HCC, especially in the metastatic setting.

Methods

HCC patients with extrahepatic metastatic lesions were enrolled that were evaluated by 18F FDG-PET before palliative systemic therapy, between January 2002 and December 2009 at the Seoul National University Hospital. We retrospectively analyzed the clinical outcome and the value of the SUVmax.

Results

A total of 25 patients (men, 88.0%) were enrolled. The response rate and disease control rate was 18.2% (95% CI: 2.1–34.3) and 32.0% (95% CI: 16.3–56.5), respectively. The progression-free survival (PFS) and overall survival (OS) were 2.3 months (95% CI: 1.1–3.4) and 14.2 months (95% CI: 9.1–19.2), respectively. The univariate analysis of OS showed that SUVmax and alphafetoprotein (AFP) were significant prognostic factors (P = 0.023 and P = 0.006, respectively). The multivariate analysis of OS showed that SUVmax and AFP were significant prognostic factors (P = 0.008 and P = 0.006, respectively). SUVmax and AFP were independent prognostic factors for PFS, too (P = 0.010 and P = 0.016, respectively). When the patients were divided according to the SUVmax and AFP, the patients with an SUVmax < 4.9 and an AFP ≤ 400 ng/ml showed longer OS and PFS than the patients with SUVmax ≥ 4.9 or AFP > 400 ng/ml (26.7 months vs. 9.3 months, P < 0.001 and 5.6 months vs. 1.7 months, P = 0.012, respectively).

Conclusions

The SUVmax of the 18F FDG-PET has a prognostic value for OS and PFS in patients with metastatic HCC undergoing systemic therapy. The combined analysis of the SUVmax with AFP might provide more detailed prognostic information.

Keywords

Positron emission tomographyStandardized uptake valueHepatocellular carcinomaSystemic therapyPrognostic factor

Copyright information

© Springer-Verlag 2010